BIOMAT Database Logo BIOMAT Database Logo

Controlled release of morphine from a poloxamer 407 gel. 2013

Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Midden-Brabant Hospital Pharmacy, TweeSteden Hospital and St. Elisabeth Hospital, Tilburg, The Netherlands. mjansen@tsz.nl

Treatment of painful ulcers is discouraging. Topical morphine has been described as a useful therapeutic adjunct in some patients. In the development of a new analgesic product, we studied the in vitro release characteristics of a new topical formulation containing 0.5% (w/w) morphine-HCl in a poloxamer 407 (P407) based gel. A diffusion cell was used for measurement of in vitro release characteristics. The donor compartment (DC) and the receptor compartment (RC) were separated by a 5000 Da cellulose acetate membrane. The morphine-HCl release from this developed P407 based gel followed zero-order kinetics with a constant release of 150 μg cm(-2)h(-1). Our results support the use of this P407 gel as a sustained release topical formulation in the pharmacological treatment of painful ulcers. Future research welcomes a formulation with release characteristics leading to less frequent application.

UI MeSH Term Description Entries
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D002482 Cellulose A polysaccharide with glucose units linked as in CELLOBIOSE. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations. Alphacel,Avicel,Heweten,Polyanhydroglucuronic Acid,Rayophane,Sulfite Cellulose,alpha-Cellulose,Acid, Polyanhydroglucuronic,alpha Cellulose
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D020442 Poloxamer A nonionic polyoxyethylene-polyoxypropylene block co-polymer with the general formula HO(C2H4O)a(-C3H6O)b(C2H4O)aH. It is available in different grades which vary from liquids to solids. It is used as an emulsifying agent, solubilizing agent, surfactant, and wetting agent for antibiotics. Poloxamer is also used in ointment and suppository bases and as a tablet binder or coater. (Martindale The Extra Pharmacopoeia, 31st ed) Pluronic,Poloxamers,Pluronic F-108,Pluronic F-127,Pluronic F-68,Pluronic F68,Pluronic L-101,Pluronic L-121,Pluronic L-81,Pluronics,Poloxalkol,Poloxamer 188,Poloxamer 213,Poloxamer 2930,Poloxamer 338,Poloxamer 407,188s, Poloxamer,213s, Poloxamer,2930s, Poloxamer,338s, Poloxamer,407s, Poloxamer,F68s, Pluronic,Pluronic F 108,Pluronic F 127,Pluronic F 68,Pluronic F108,Pluronic F127,Pluronic F68s,Pluronic L 101,Pluronic L 121,Pluronic L 81,Pluronic L101,Pluronic L121,Pluronic L81,Poloxalkols,Poloxamer 188s,Poloxamer 213s,Poloxamer 2930s,Poloxamer 338s,Poloxamer 407s

Related Publications

Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Controlled release of vancomycin from poloxamer 407 gels.
December 1999, International journal of pharmaceutics,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Poloxamer 407 based-nanoparticles for controlled release of methotrexate.
February 2020, International journal of pharmaceutics,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Sustained release of lidocaine from Poloxamer 407 gels.
January 2005, International journal of pharmaceutics,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur.
December 2002, Journal of controlled release : official journal of the Controlled Release Society,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
[In vitro and in vivo biodegradation of sustained-release vehicle poloxamer 407 in situ gel].
January 2008, Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model.
November 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Sustained-release of urease from a poloxamer gel matrix.
January 1990, Journal of parenteral science and technology : a publication of the Parenteral Drug Association,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Characterization of rabies pDNA nanoparticulate vaccine in poloxamer 407 gel.
July 2018, International journal of pharmaceutics,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Measuring antimicrobial susceptibility of Pseudomonas aeruginosa using Poloxamer 407 gel.
April 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Mark M P M Jansen, and Jacques M Verzijl, and David M Burger, and Yechiel A Hekster
Contact anaphylaxis to poloxamer 188 and 407 in a periodontal gel.
March 2021, Contact dermatitis,
Copied contents to your clipboard!